Most Popular Stories
- Ben Venue can't say when crucial cancer drug will be available
- Gene study finds tumor-cell flaw possibly vulnerable to Pfizer, AZ cancer meds
- Ben Venue's idled plant triggers 'dire' leukemia-drug shortage
- The best of times, the worst of times?
- Pioneering stem cell therapy mends damaged heart tissue in patients
- Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
- InnaVirVax nabs $4.9M in B round to advance HIV immunotherapy
- Actelion hunts for answers about 120 deaths in key drug trial
- Pfizer R&D chief talks up chances for late-stage Alzheimer's drug
- Karo Bio walks away from Phase III cholesterol drug due to safety risks
- Biogen Idec scores lung disease drug in $562.5M buyout of Stromedix
Webinars
- Active Directory & the Cloud for Biotech & PharmaBiotech and pharmaceutical companies are leaders cloud/SaaS technology adoption. This webi
- Inside the mHealth Revolution with Welch Allyn: Realizing the Potential of Connected DevicesAfter launching a line of connected devices, Welch Allyn immediately viewed it as an oppor
- Getting the most out of First-in-Human and Early Clinical TrialsIn a follow-up to our webinar last month on first-in-human drug studies, FierceBiotech edi
- Special Studies in Cancer Patients: AME and Cardiac SafetyFierceBiotech Editor John Carroll will moderate an expert panel discussion exploring how c
Featured Jobs
-
Clinical Research Associate
Jennerex, Inc - San Francisco, CA -
Manager Business Development
Clinical Resource Network - US West Coast -
District Sales Manager – Hematology, Denver / Phoenix Job
Celgene Corporation - Denver, CO, US -
Facilities Project Manager
Genomics Institute of the Novartis Research Foundation - San Diego, CA -
Associate Manager, Global Supply Chain Planning (1 of 3) Job
Celgene Corporation - Basking Ridge, NJ, US
Events
- Euro-Biotech Partnering Summit
May 30-June 1, 2012 — Paris, France - DCAT Week '12 Biologics Forum & Networking Reception
Mar 14 — New York City - Connect, Collaborate, & Innovate: MassBio Annual Meeting
March 26-27 — Cambridge, MA - World Orphan Drug Congress USA 2012
10-13 April, 2012 — Gaylord National Resort and Convention Center, Washington, D.C.
Free Newsletter
FierceBiotech is the biotech industry's daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and FDA approval news. Join 90,000+ biotechnology and pharma industry professionals who get FierceBiotech via daily email. Sign up today!
Popular Topics
Whitepapers
- Displacement Chromatography Comes of Age - An indispencable tool for the purification of biomacromolecules
- The Cutting Edge of Chemistry
- The Voice of the Site Coordinator
- cTQM (Clinical Total Quality Management)
- Retaining Brand Loyalty
- The Top 10 Biotechnology Companies: Positioning, performance and SWOT analyses
Which company do you think has the strongest pipeline?
Pfizer
9%
Johnson & Johnson
6%
GlaxoSmithKline
13%
Sanofi-Aventis
7%
Roche
11%
Novartis
16%
Merck
10%
AstraZeneca
3%
Amgen
5%
Bayer
1%
Eli Lilly
5%
Wyeth
4%
Bristol-Myers Squibb
3%
Abbott
3%
Schering-Plough
4%
Total votes: 274
